Trial reportCell death & disease2020
Increased AT
Trial report in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- GPCRs identified on mitochondrial membranes: New therapeutic targets for diseases.Journal of pharmaceutical analysis · 2025Review
- Renin-Angiotensin System Autoantibody Network in Parkinson's Disease Patients.Antioxidants (Basel, Switzerland) · 2025Article
- Serum angiotensin type-1 receptor autoantibodies and neurofilament light chain as markers of neuroaxonal damage in post-COVID patients.Frontiers in immunology · 2025Article
- Angiotensin II constricts mouse iliac arteries: possible mechanism for aortic aneurysms.Molecular and cellular biochemistry · 2024Article
- Melatonin stabilizes atherosclerotic plaques: an association that should be clinically exploited.Frontiers in medicine · 2024Review
- Identification of autophagy-associated circRNAs in sepsis-induced cardiomyopathy of mice.Scientific reports · 2023Article
- Bioinformatics analysis of KLF2 as a potential prognostic factor in ccRCC and association with epithelial-mesenchymal transition.Experimental and therapeutic medicine · 2022Article
- Large-Conductance Calcium-Activated Potassium Channel Opener, NS1619, Protects Against Mesenteric Artery Remodeling Induced by Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor.Journal of the American Heart Association · 2022Article
- Anti-AT1R autoantibodies and prediction of the severity of Covid-19.Human immunology · 2022Article
- Emerging Roles of Circular RNAs in Vascular Smooth Muscle Cell Dysfunction.Frontiers in genetics · 2021Review
- The development and controversy of competitive endogenous RNA hypothesis in non-coding genes.Molecular and cellular biochemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular remodeling can be caused by angiotensin II type 1 receptor (AT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.